Publicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (10)

2023

  1. Description of a different quantification method for amyloid burden (burdenDPD) and validation of SPECT/CT in cardiac amyloidosis

    Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 42, Núm. 3, pp. 171-177

1989

  1. Circulating CA 15-3 antigen levels in non-mammary malignancies

    British Journal of Cancer, Vol. 59, Núm. 2, pp. 283-286

  2. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases

    Breast Cancer Research and Treatment, Vol. 13, Núm. 2, pp. 123-133

  3. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease

    Cancer, Vol. 64, Núm. 8, pp. 1674-1681

1986

  1. Circulating CA 15.3 levels in breast cancer. Our present experience.

    The International journal of biological markers, Vol. 1, Núm. 2, pp. 89-92

  2. Evaluation of specific antigen and prostatic acid phosphatase specificity. Study of false values.

    The International journal of biological markers, Vol. 1, Núm. 3, pp. 141-146

  3. Serum CA 19.9 levels in patients with non tumoral pathologies. Our experience in 892 cases

    Bulletin du Cancer, Vol. 73, Núm. 3, pp. 256-259

1985

  1. EL ANTIGENO PROSTATICO ESPECIFICO. NUEVO MARCADOR TUMORAL

    Medicina Clinica, Vol. 85, Núm. 19, pp. 801-804

  2. ESTUDIO DE LA COLIGLICINA Y LA SULFOLITOCOLIGLICINA POSPRANDIALES EN LAS HEPATOPATIAS FOCALES Y DIFUSAS

    Medicina Clinica, Vol. 85, Núm. 16, pp. 653-655

1984

  1. CA125 seric levels in non malignant pathologies

    Bulletin du Cancer